These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33212064)

  • 1. Patisiran in hereditary transthyretin-mediated amyloidosis.
    Luigetti M; Servidei S
    Lancet Neurol; 2021 Jan; 20(1):21-23. PubMed ID: 33212064
    [No Abstract]   [Full Text] [Related]  

  • 2. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
    Yang J
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 4. Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study".
    Solomon SD
    Circulation; 2019 Jul; 140(2):e92-e93. PubMed ID: 31283371
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter by González-Costello et al Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Study".
    González-Costello J; Casasnovas C; Díez-López C
    Circulation; 2019 Jul; 140(2):e90-e91. PubMed ID: 31283374
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Lin H; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Aug; 20(12):1529-1530. PubMed ID: 31124741
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Salvo EM; Samjoo IA; Tran D; Cameron C
    Expert Opin Pharmacother; 2019 Aug; 20(12):1527-1528. PubMed ID: 31124724
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
    Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
    J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP; Yang CC; Lee YC; Lee MJ; Vest J; Sweetser MT; White MT; Badri P; Hsieh ST; Chao CC
    J Formos Med Assoc; 2024 Sep; 123(9):975-984. PubMed ID: 38548524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
    JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nerve ultrasonography features in hereditary transthyretin amyloidosis with V30M mutation and polyneuropathy.
    Salvalaggio A; Coraci D; Cacciavillani M; Padua L; Briani C
    Neurol Sci; 2021 Jun; 42(6):2547-2548. PubMed ID: 33415458
    [No Abstract]   [Full Text] [Related]  

  • 16. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL; Claeys KG; Delstanche S; Van Parys V; Baets J; Tilleux S; Remiche G
    Acta Neurol Belg; 2023 Jun; 123(3):1029-1037. PubMed ID: 36829087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy.
    Müschen LH; Körner G; Gingele S; Hänselmann A; Bavendiek U; Skripuletz T
    Muscle Nerve; 2021 Sep; 64(3):E11-E13. PubMed ID: 34075597
    [No Abstract]   [Full Text] [Related]  

  • 18. Vutrisiran: First Approval.
    Keam SJ
    Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis.
    Patel RK; Fontana M; Hawkins PN; Gillmore J
    Amyloid; 2021 Dec; 28(4):269-270. PubMed ID: 33945356
    [No Abstract]   [Full Text] [Related]  

  • 20. Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.
    Goel V; Gosselin NH; Jomphe C; Zhang X; Marier JF; Robbie GJ
    Nucleic Acid Ther; 2020 Jun; 30(3):143-152. PubMed ID: 32175804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.